A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...
Providing surgeons feedback and education on their performance significantly improved the quality of bladder cancer ...
Scientists uncovered how childhood BK virus infections may set off cancer-causing mutations decades later: by activating a ...
Man patients with MIBC are ineligible for or refuse SOC cisplatin. SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic ...
EMA recommends conditional marketing authorisation for Serum Life Science Europe’s Anktiva to treat non-muscle invasive bladder cancer: Amsterdam, The Netherland Monday, Decembe ...
ImmunityBio recently reported that the European Medicines Agency recommended granting conditional marketing authorization for ANKTIVA, in combination with BCG, to treat BCG-unresponsive non-muscle ...
Tackling a common childhood virus could open the door to preventing bladder cancer, according to new research.
EMA recommends conditional authorization for ImmunityBio's Anktiva with BCG after a 71% complete response rate in ...
Researchers in the United Kingdom have found a common childhood virus that can trigger DNA damage leading to bladder cancer ...
When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...
ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with ...
What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback